Enanta Pharmaceuticals (ENTA) Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ENTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENTA, but not buy additional shares or sell existing shares.
View ENTA analyst ratings or view top-rated stocks.

8 analysts have issued 1 year target prices for Enanta Pharmaceuticals' shares. Their ENTA share price forecasts range from $14.00 to $87.00. On average, they predict the company's stock price to reach $38.50 in the next year. This suggests a possible upside of 205.1% from the stock's current price.
View analysts price targets for ENTA or view top-rated stocks among Wall Street analysts.

Enanta Pharmaceuticals' stock was trading at $46.52 at the beginning of the year. Since then, ENTA stock has decreased by 72.9% and is now trading at $12.62.
View the best growth stocks for 2023 here.

Enanta Pharmaceuticals saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 1,680,000 shares, an increase of 16.7% from the August 15th total of 1,440,000 shares. Based on an average daily trading volume, of 278,600 shares, the days-to-cover ratio is currently 6.0 days. Approximately 8.6% of the shares of the company are short sold.
View Enanta Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 20th 2023.
View our ENTA earnings forecast.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) released its quarterly earnings results on Monday, August, 7th. The biotechnology company reported ($1.86) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.38) by $0.52. The biotechnology company earned $18.89 million during the quarter, compared to the consensus estimate of $15.88 million. Enanta Pharmaceuticals had a negative net margin of 163.87% and a negative trailing twelve-month return on equity of 46.77%.

ETFMG Treatments Testing and Advancements ETF holds 5,945 shares of ENTA stock, representing 0.75% of its portfolio.

Enanta Pharmaceuticals updated its third quarter earnings guidance on Monday, August, 7th. The company provided earnings per share guidance of ($1.86) for the period, compared to the consensus earnings per share estimate of ($2.25). The company issued revenue guidance of $18.9 million, compared to the consensus revenue estimate of $18.19 million.

5 employees have rated Enanta Pharmaceuticals Chief Executive Officer Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among the company's employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Enanta Pharmaceuticals to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS).

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Enanta Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (17.71%), State Street Corp (7.21%), Northern Trust Corp (4.63%), Krensavage Asset Management LLC (3.27%), Renaissance Technologies LLC (2.26%) and Dimensional Fund Advisors LP (2.12%). Insiders that own company stock include Bruce L A Carter, Jay R Luly, Nathalie Adda, Paul J Mellett and Yat Sun Or.
View institutional ownership trends.

Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ENTA stock can currently be purchased for approximately $12.62.

Enanta Pharmaceuticals (NASDAQ:ENTA) has a market capitalization of $265.78 million and generates $86.16 million in revenue each year. The biotechnology company earns $-121,750,000.00 in net income (profit) each year or ($6.31) on an earnings per share basis.

The company employs 160 workers across the globe.

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The official website for the company is www.enanta.com. The biotechnology company can be reached via phone at (617) 607-0800, via email at cmiceli@enanta.com, or via fax at 617-607-0530.